SOLV · Solventum Corporation
$77.64
+1.00% last session
End-of-day data · updated 2026-07-24
Market cap
$13B
Enterprise value
$18B
Trailing P/E
9.5
Forward P/E
10.9
Dividend yield
—
Beta
0.72
Avg volume
2M
Employees
21K
2D change
-0.52%
5D change
-5.01%
10D change
1.26%
30D change
2.18%
60D change
0.53%
MTD change
-1.42%
YTD change
-2.52%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — SOLV
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-28
Latest call per bank · past 12 months
UBS
Buy$95.00
+22.4% vs priceWells Fargo
Equal-Weight$70.00
-9.8% vs priceJefferies
Hold$80.00
+3.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-28 | UBS | Upgrade | Neutral → Buy | $0.00 → $95.00 |
| 2026-07-09 | BMO Capital | Initiates | Market Perform | $0.00 → $81.00 |
| 2026-05-15 | Wedbush | Initiates | Outperform | $0.00 → $94.00 |
| 2026-05-06 | UBS | Maintains | Neutral | $82.00 → $78.00 |
| 2026-05-06 | Stifel | Maintains | Buy | $105 → $90.00 |
| 2026-05-06 | Wells Fargo | Maintains | Equal-Weight | $83.00 → $70.00 |
| 2026-05-06 | Keybanc | Maintains | Overweight | $92.00 → $93.00 |
| 2026-05-06 | BTIG | Reiterates | Buy | $89.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-24
- RSI (14): RSI is 51 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 0.9% above the 50-day MA ($77.30).
- Price vs 200-day MA: Trading 4.1% above the 200-day MA ($74.91).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.09) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($62.49) and high ($86.14).
SOLV Price Chart
Loading chart for SOLV…
Fundamentals
About Solventum Corporation
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.
More in Medical Instruments & Supplies
ISRG
Intuitive Surgical, Inc.
$119B -41.4% YTD
MDLN
Medline Inc.
$67B -10.4% YTD
BDX
Becton, Dickinson and Company
$42B 1.6% YTD
ALC
Alcon Inc.
$33B -14.3% YTD
RMD
ResMed Inc.
$28B -19.9% YTD
WST
West Pharmaceutical Services, I
$25B 29.4% YTD
COO
The Cooper Companies, Inc.
$14B -14.3% YTD
ALGN
Align Technology, Inc.
$12B 7.7% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.